Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer).

BACKGROUND First-line chemotherapy regimens suitable for elderly advanced breast cancer patients are still not defined. PATIENTS AND METHODS Women with stage III or IV breast cancer aged > or =70 years were enrolled in a phase II study aimed to evaluate both activity and toxicity of weekly paclitaxel. Among 46 planned patients, at least 18 responses and not more than seven unacceptable toxic events are required for a favourable conclusion. Paclitaxel 80 mg/m(2) was administered weekly for 3 weeks every 28 days. RESULTS Unacceptable toxicity occurred in seven out of 46 patients evaluated for toxicity [15.2%; exact 95% confidence interval (CI) 7.6% to 28.2%] and was represented by one case of febrile neutropenia, one case of severe allergic reaction and five cases of cardiac toxicity. Among 41 patients evaluated for response, a complete response occurred in two (4.9%) patients and a partial response in 20 (48.8%), with an overall response rate of 53.7% (exact 95% CI 38.7% to 67.9%). The median progression-free survival was 9.7 months (95% CI 8.5-18.7) and median survival was 35.8 months (95% CI 19-not defined). CONCLUSIONS Weekly paclitaxel is highly active in elderly advanced breast cancer patients. Data on cardiovascular complications, however, indicate the need for a careful monitoring of cardiac function before and during chemotherapy.

[1]  L. Repetto,et al.  Weekly Paclitaxel in Elderly Patients with Advanced Breast Cancer , 2004, Drugs in R&D.

[2]  G. Hortobagyi,et al.  Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Cantor,et al.  Can older cancer patients tolerate chemotherapy? , 2003, Cancer.

[4]  C. Hudis,et al.  Cardiac dysfunction in the trastuzumab clinical trials experience. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  W. Gianni,et al.  Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  E. Perez,et al.  Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Hainsworth,et al.  Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Platania,et al.  Safety and activity of Capecitabine in elderly patients with advanced breast cancer , 2001 .

[9]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[10]  S. Goodman,et al.  A Prospective Pharmacologic Evaluation of Age-Related Toxicity of Adjuvant Chemotherapy in Women with Breast Cancer , 2000, Cancer investigation.

[11]  C. Vogel,et al.  Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  C. Hudis,et al.  Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  L. Mariani,et al.  Oral doxifluridine plus levoleucovorin in elderly patients with advanced breast cancer , 1998, Cancer.

[14]  C. Tibaldi,et al.  Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  L. Ferrucci,et al.  Validation of a multidimensional evaluation scale for use in elderly cancer patients , 1996, Cancer.

[16]  G. Hortobagyi,et al.  Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome. , 1996, Archives of internal medicine.

[17]  J. Bryant,et al.  Incorporating toxicity considerations into the design of two-stage phase II clinical trials. , 1995, Biometrics.

[18]  M. Gasco,et al.  Mitoxantrone in elderly women with advanced breast cancer: a phase II study. , 1995, Anticancer research.

[19]  N. Petrelli,et al.  Age and sex are independent predictors of 5‐fluorouracil toxicity. Analysis of a large scale phase III trial , 1995, Cancer.

[20]  J. Gold,et al.  Validation of a combined comorbidity index. , 1994, Journal of clinical epidemiology.

[21]  R. Gelber,et al.  Adjuvant systemic therapy for breast cancer in the elderly: competing causes of mortality. International Breast Cancer Study Group. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  R. Gelman,et al.  Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Sydney Katz Assessing Self‐maintenance: Activities of Daily Living, Mobility, and Instrumental Activities of Daily Living , 1983, Journal of the American Geriatrics Society.

[24]  M. Lawton,et al.  Assessment of older people: self-maintaining and instrumental activities of daily living. , 1969, The Gerontologist.